Restoration of DC function, increased CD8+ T-cell and NK-cell infiltration, T-cell cytotoxicity (perforin, granzyme B), and melanoma antigen presentation, with a decrease in IL-6, IL-8, and CCL2 were observed in mouse melanoma models and patient biopsies treated with a BRAF inhibitor with or without concurrent MEK inhibition [41,42,43]. This evidence concerns the gene MAP2K7 and melanoma.